Prokarium snags $21m Series B
London-based Prokarium, a developer of novel immunotherapies and vaccines based on its engineered microbial platform, has raised $21 million in Series B funding.
London-based Prokarium, a developer of novel immunotherapies and vaccines based on its engineered microbial platform, has raised $21 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination